Aldeyra Therapeutics, Inc. (ALDX)

Market Cap	193.10M
Revenue (ttm)	n/a
Net Income (ttm)	-30.01M
Shares Out	59.41M
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	237,387
Open	3.280
Previous Close	3.250
Day's Range	3.160 - 3.310
52-Week Range	1.420 - 8.380
Beta	1.39
Analysts	Strong Buy
Price Target	9.33 (+187.08%)
Earnings Date	Aug 1, 2024

About ALDX

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 2, 2014
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: ALDX

Analyst Forecast

According to 4 analysts, the average rating for ALDX stock is "Strong Buy." The 12-month stock price forecast is $9.33, which is an increase of 187.08% from the latest price.

Price Target

$9.33

(187.08% upside)

Analyst Consensus: Strong Buy